Therapies
0
Secukinumab (Cosentyx):Secukinumab is an Interleucin-17A (IL-17A) inhibitor, initially developed and approved for the treatment of moderate to severe ...
Secukinumab (Cosentyx):Secukinumab is an Interleucin-17A (IL-17A) inhibitor, initially developed and approved for the treatment of moderate to severe ...